Literature DB >> 18273567

Cardiac troponin I as prognostic marker in heart failure patients discharged from emergency department.

Nicola Parenti1, Silvia Bartolacci, Flavia Carle, Fanciulli Angelo.   

Abstract

Despite evidence that cardiac troponin I (cTnI) identifies patients with advanced heart failure (HF) at risk of death, data on heterogeneous HF populations are scarce. Our purpose was to verify and analyze the prognostic role of cTnI in acute HF patients admitted to the emergency department. This was an observational longitudinal prospective study carried out in an urban hospital. We studied 99 patients discharged from the department between March and December 2002 with a HF diagnosis and samples of cTnI. Patients with acute coronary syndromes, myocarditis or renal failure were excluded. The main outcome was death from any cause. The detection level of the cTnI assay was 0.05 ng/ml. cTnI was detected in 45.5% of HF patients. These patients had a higher NYHA class (P<0.001) at initial presentation and longer hospitalization (P=0.004) than cTnI-negative patients. Nineteen deaths occurred during the study: 17 for HF and 2 for acute coronary syndrome. Finally, detectable cTnI was associated with increased mortality risk (RR 4.7; 95% CI 1.3-17.1; P=0.021) also after adjustment for other adverse prognosis factors (age, NYHA class and presence of relapses). Our HF cTnI-positive patients had a worse clinical presentation and longer hospitalization. cTnI is a significant independent predictor of death and of longer hospitalization. It could be used for the early identification of HF patients at an increased risk of death in the long term, and of longer hospitalization. Thus, cTnI can aid decision-making and clinical management in the emergency department.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18273567     DOI: 10.1007/s11739-008-0092-8

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  32 in total

1.  Correlations between clinical presentation, brain natriuretic peptide, big endothelin-1, tumor necrosis factor-alpha and cardiac troponins in heart failure patients.

Authors:  Giovanni Maria Boffa; Martina Zaninotto; Enrico Bacchiega; Chiara Nalli; Massimo Forni; Enrico Tiso; Luisa Cacciavillani; Renato Razzolini; Mario Plebani
Journal:  Ital Heart J       Date:  2005-02

2.  The Pilot Randomized Study of Nesiritide Versus Dobutamine in Heart Failure (PRESERVD-HF).

Authors:  Mihai Gheorghiade; Wendy Gattis Stough; Kirkwood F Adams; Allan S Jaffe; Victor Hasselblad; Christopher M O'Connor
Journal:  Am J Cardiol       Date:  2005-09-19       Impact factor: 2.778

3.  Higher New York Heart Association classes and increased mortality and hospitalization in patients with heart failure and preserved left ventricular function.

Authors:  Ali Ahmed; Wilbert S Aronow; Jerome L Fleg
Journal:  Am Heart J       Date:  2006-02       Impact factor: 4.749

4.  Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes.

Authors:  E M Antman; M J Tanasijevic; B Thompson; M Schactman; C H McCabe; C P Cannon; G A Fischer; A Y Fung; C Thompson; D Wybenga; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-31       Impact factor: 91.245

5.  One-year mortality among unselected outpatients with heart failure.

Authors:  J Muntwyler; G Abetel; C Gruner; F Follath
Journal:  Eur Heart J       Date:  2002-12       Impact factor: 29.983

6.  Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

Authors: 
Journal:  N Engl J Med       Date:  1987-06-04       Impact factor: 91.245

7.  The epidemiology of heart failure: the Framingham Study.

Authors:  K K Ho; J L Pinsky; W B Kannel; D Levy
Journal:  J Am Coll Cardiol       Date:  1993-10       Impact factor: 24.094

Review 8.  Biochemical markers of myocyte injury in heart failure.

Authors:  Y Sato; T Kita; Y Takatsu; T Kimura
Journal:  Heart       Date:  2004-10       Impact factor: 5.994

9.  Cardiac troponin I as a predictor of major cardiac events in emergency department patients with acute chest pain.

Authors:  C A Polanczyk; T H Lee; E F Cook; R Walls; D Wybenga; G Printy-Klein; L Ludwig; G Guldbrandsen; P A Johnson
Journal:  J Am Coll Cardiol       Date:  1998-07       Impact factor: 24.094

10.  Usefulness of an elevated troponin-I in predicting clinical events in patients admitted with acute heart failure and acute coronary syndrome (from the RITZ-4 trial).

Authors:  Wendy A Gattis; Christopher M O'Connor; Vic Hasselblad; Kirkwood F Adams; Isaac Kobrin; Mihai Gheorghiade
Journal:  Am J Cardiol       Date:  2004-06-01       Impact factor: 2.778

View more
  9 in total

1.  Role of Cardiac Troponin Levels in Acute Heart Failure.

Authors:  Nicholas Wettersten; Alan Maisel
Journal:  Card Fail Rev       Date:  2015-10

Review 2.  Diagnosing destabilized heart failure in the emergency setting: current and future biomarker tests.

Authors:  Damien Gruson; Frédéric Thys; Franck Verschuren
Journal:  Mol Diagn Ther       Date:  2011-12-01       Impact factor: 4.074

3.  Predictors of Post-discharge Mortality Among Patients Hospitalized for Acute Heart Failure.

Authors:  Ovidiu Chioncel; Sean P Collins; Stephen J Greene; Peter S Pang; Andrew P Ambrosy; Elena-Laura Antohi; Muthiah Vaduganathan; Javed Butler; Mihai Gheorghiade
Journal:  Card Fail Rev       Date:  2017-11

4.  Improving prognosis estimation in patients with heart failure and the cardiorenal syndrome.

Authors:  Husam M Abdel-Qadir; Shaan Chugh; Douglas S Lee
Journal:  Int J Nephrol       Date:  2011-05-18

5.  Predictive factors for longer length of hospital stay in patients with heart failure.

Authors:  Can Ramazan Öncel
Journal:  Anatol J Cardiol       Date:  2019-02       Impact factor: 1.596

6.  Evaluation of a sensitive cardiac troponin I assay as a screening test for the diagnosis of hypertrophic cardiomyopathy in cats.

Authors:  S Hertzsch; A Roos; G Wess
Journal:  J Vet Intern Med       Date:  2019-04-16       Impact factor: 3.333

7.  Rivaroxaban Once-Daily vs. Dose-Adjusted Vitamin K Antagonist on Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF): Rationale and Design of an Investigator-Initiated Multicenter Randomized Prospective Open-Labeled Pilot Clinical Study.

Authors:  Iksung Cho; Jaewon Oh; In-Cheol Kim; Hyemoon Chung; Jung-Hee Lee; Hyue Mee Kim; Young Sup Byun; Byung-Su Yoo; Eui-Young Choi; Wook-Jin Chung; Wook Bum Pyun; Seok-Min Kang
Journal:  Front Cardiovasc Med       Date:  2022-01-12

8.  High-sensitivity troponin T: a biomarker for diuretic response in decompensated heart failure patients.

Authors:  João Pedro Ferreira; Mário Santos; Sofia Almeida; Irene Marques; Paulo Bettencourt; Henrique Carvalho
Journal:  Cardiol Res Pract       Date:  2014-08-28       Impact factor: 1.866

Review 9.  Serelaxin: a novel therapy for acute heart failure with a range of hemodynamic and non-hemodynamic actions.

Authors:  Javier Díez
Journal:  Am J Cardiovasc Drugs       Date:  2014-08       Impact factor: 3.571

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.